Lipricain 25+25 mg/g creme Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

lipricain 25+25 mg/g creme

teva b.v. - lidocain, prilocain - creme - 25+25 mg/g

Emla 25+25 mg/g creme Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

emla 25+25 mg/g creme

aspen pharma trading limited - lidocain, prilocain - creme - 25+25 mg/g

Tapin 2,5 %+2,5 % creme Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

tapin 2,5 %+2,5 % creme

orifarm generics a/s - lidocain, prilocain - creme - 2,5 %+2,5 %

Ovestin 1 mg/g vaginalcreme Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ovestin 1 mg/g vaginalcreme

aspen pharma trading ltd. - estriol - vaginalcreme - 1 mg/g

Ovestin 1 mg/g vaginalcreme Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ovestin 1 mg/g vaginalcreme

orifarm a/s - estriol - vaginalcreme - 1 mg/g

Ovestin 1 mg/g vaginalcreme Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ovestin 1 mg/g vaginalcreme

2care4 aps - estriol - vaginalcreme - 1 mg/g

Axhidrox 2,2 mg/dosis creme Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

axhidrox 2,2 mg/dosis creme

dr. august wolff gmbh & co. kg arzneimittel - glycopyrroniumbromid - creme - 2,2 mg/dosis

Nulbia 25+25 mg/g creme Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

nulbia 25+25 mg/g creme

terix labs ltd. - lidocain, prilocain - creme - 25+25 mg/g

Estriol "Paranova" 1 mg/g vaginalcreme Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

estriol "paranova" 1 mg/g vaginalcreme

paranova danmark a/s - estriol - vaginalcreme - 1 mg/g

Yesafili Den Europæiske Union - dansk - EMA (European Medicines Agency)

yesafili

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmologiske - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.